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The heat shock protein HSP70 plays antiapoptotic
and oncogenic roles, and thus its inhibition has
been recognized as a potential avenue for anticancer
therapy. Here we describe the small molecule, apop-
tozole (Az), which inhibits the ATPase activity of
HSP70 by binding to its ATPase domain and, as a
result, induces an array of apoptotic phenotypes in
cancer cells. Affinity chromatography provides evi-
dence that Az binds HSP70 but not other types of
heat shock proteins including HSP40, HSP60, and
HSP90. We also demonstrate that Az induces cancer
cell death via caspase-dependent apoptosis by dis-
rupting the interaction of HSP70with APAF-1. Animal
studies indicate that Az treatment retards tumor
growth in a xenograft mouse model without affecting
mouse viability. These studies suggest that Az will
aid the development of new cancer therapies and
serve as a chemical probe to gain a better under-
standing of the diverse functions of HSP70.
INTRODUCTION
Apoptosis, or programmed cell death, is a fundamental biolog-
ical process which is involved in normal development, regulation
of the immune system, development of the nervous system, and
tissue homeostasis (Baek et al., 2012; Beere, 2005; Newmeyer
and Ferguson-Miller, 2003). A large body of literature indicates
that the heat shock protein 70 (HSP70) family has multiple func-
tions involved in suppression of apoptotic pathways (Ciocca and
Calderwood, 2005; Garrido et al., 2006; Jaattela, 1995; Pocaly
et al., 2006; Volloch and Sherman, 1999). The two major cyto-
solic isoforms of the HSP70 family are HSC70 (a heat shock
cognate 70 protein) and HSP70 (an inducible HSC70 homolog
protein). Whereas HSC70 is constitutively and ubiquitously ex-
pressed, HSP70 is present at relatively low levels in normal cellsChemistry & Biology 22, 3under non-stressful conditions (Daugaard et al., 2007). However,
in response to various stressful stimuli, including heat and oxida-
tive stress, and anticancer agents, the expression level of HSP70
is elevated to protect cells from apoptosis (Lui and Kong, 2007;
Mosser et al., 1997; Plumier et al., 1995; Welch and Suhan,
1986). In addition to its role in the stress response, HSP70 dis-
plays chaperone activities including protein folding, suppression
of the aggregation of denatured proteins, degradation of mis-
folded proteins, protein translocation, and modulation of the
assembly and disassembly of protein complexes (Bukau and
Horwich, 1998; Young et al., 2004).
HSP70 consists of an N-terminal ATPase domain (or nucleo-
tide binding domain) and a C-terminal substrate binding domain
(SBD) that recognizes polypeptide substrates. The two domains
are functionally coupled in such a way that hydrolysis of ATP to
ADP by the ATPase activity of HSP70 results in conformational
changes in the adjacent SBD that lead to an increase in binding
affinities for substrates (Daugaard et al., 2007; Swain et al.,
2007). Normally, the ATP-bound form of HSP70 has relatively
weak affinity for substrates whereas the ADP-bound protein
strongly binds substrates. This feature suggests that ATP hydro-
lysis is a major driving force for the conformational change and
chaperone activity of HSP70.
The expression level of HSP70 is known to increase greatly in
various cancers, a phenomenon that leads to tumor cell survival
via multiple antiapoptotic processes (Ciocca and Calderwood,
2005; Garrido et al., 2006; Pocaly et al., 2006). Overexpression
of HSP70 is correlated with tumor resistance to chemothera-
peutic agents, such as imatinib, cisplatin, and etoposide, and
poor prognosis in multiple forms of cancer (Gabai et al., 2005;
Mosser andMorimoto, 2004; Pocaly et al., 2006). The tumor-pro-
tective effects of HSP70 are particularly noticeable when cancer
cells are treated with inhibitors (e.g. geldanamycin and its deriv-
atives) of HSP90, a potent target for cancer chemotherapy. Spe-
cifically, treatment of cancer cells with these inhibitors results in
production of HSP70, thereby leading to a decrease in the can-
cer cell death effect of HSP90 inhibitors (Bagatell et al., 2000;
Wu, 1995).
Owing to its antiapoptotic and oncogenic functions, HSP70
has become an important target for anticancer therapy. To91–403, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 391
Figure 1. Az Inhibits ATPase Activity of
HSP70 by Binding to its ATPase Domain
(A) Chemical structure of Az and Az-linked resin.
(B) Az-linked resin was incubated with purified full-
length or truncated HSP70. Proteins bound to the
resin were visualized using silver staining.
(C) ATP-agarose resin was incubated with purified
full-length and the ATPase domain of HSP70 in the
absence or presence of 100 mM Az or 1 mM ATP.
Proteins bound to the resin were visualized using
silver staining.
(D) Az-linked resin was incubated with purified
HSP90, HSP70, and HSP40 in the absence and
presence of Az. Proteins bound to the resin were
visualized using silver staining.
(E) Az-linked resin was incubated with HeLa cell
lysates treated with Az for 1 hr. Bound proteins
were analyzed by western blot.date, several small molecules that bind to HSP70 proteins have
been developed for use as potential therapeutic agents and/or
chemical probes (Evans et al., 2010; Powers and Workman,
2007). For example, 15-deoxyspergualin (15-DSG), which binds
to the C-terminal EEVD domain of HSC70 and HSP90 but not to
HSP70, has immunosuppression and low anticancer activities
(Kaufman et al., 1996; Nadler et al., 1992). However, 15-DSG
has poor bioavailability and its mode of action has not been
well elucidated. Dihydropyrimidine derivatives have also been
identified as an inhibitor of the ATPase activity of HSP70 (Fewell
et al., 2004). Although these substances havemodest anticancer
activities (Koren et al., 2010), further studies are needed to un-
derstand the molecular mechanism of their biological effects.
Phenylethynesulfonamide (PES), which binds to the C terminus
of HSP70 but not to HSC70 and HSP90, has been shown to kill
cancer cells, presumably by disrupting the autophagic process
but not by inducing apoptosis (Leu et al., 2009). Rhodacyanine
MKT-077 has been observed to have antiproliferative activity
against cancer cells by binding in close proximity to the ATP
binding site of HSP70 (Wadhwa et al., 2000). However, the use
of this molecule as a therapeutic agent is limited because of its
rapid metabolism. Although some progress in developing small
molecules that bind to HSP70 has been made, an intense effort
is required to discover more efficacious inhibitors of HSP70 for
cancer therapy and to better understand the diverse functions
of HSP70, including its antiapoptotic role.
We recently identified the novel apoptosis-inducing small
molecule, apoptozole (Az, Figure 1A), which binds to both
HSP70 and HSC70 with similar affinities (Williams et al., 2008b;
Cho et al., 2015). However, the detailed apoptotic effect of
Az on cancer cells and mechanisms underlying Az-induced392 Chemistry & Biology 22, 391–403, March 19, 2015 ª2015 Elsevier Ltd All rights reservedapoptosis have not been elucidated. In
the effort described below, we have un-
covered evidence supporting the conclu-
sion that Az inhibits HSP70 activity by
binding to its ATPase domain, and treat-
ment of cancer cells with this substance
induces an array of apoptotic pheno-
types. The results of cell-based mecha-
nistic studies show that Az blocks theinteraction of HSP70 with APAF-1 (apoptotic peptidase acti-
vating factor 1) without interfering with its binding to ASK1
(apoptosis signal-regulating kinase 1), JNK (c-Jun N-terminal ki-
nase), BAX, and AIF (apoptosis-inducing factor). Consequently,
this substance induces cell death via caspase-dependent
apoptosis. In addition, we have shown that Az greatly retards
tumor growth in mice xenografted with cancer cells without
affecting mouse viability. The combined results arising from
cell experiments and animal studies suggest that Az has the
potential of being used as an antitumor agent.
RESULTS
Az Blocks ATPase Activity of HSP70 by Binding to the
ATPase Domain
The results of previous affinity chromatography studies suggest
that HSP70 (an inducible form) and HSC70 (a constitutive form)
are primary targets of Az (Williams et al., 2008b). As inducible
HSP70 is highly expressed in cancer cells to suppress
apoptosis, the current study focusing on HSP70 was carried
out to elucidate the molecular mechanism of apoptosis induced
by Az. In the initial phase of this effort, we determined which
domain of HSP70 was associated with Az. For this purpose,
full-length and truncated (ATPase domain and SBD) HSP70 pro-
teins were purified in the N-terminal His6-tagged forms (Fig-
ure S1A). The results of affinity chromatography studies using
an Az-linked resin show that the full-length protein and the
ATPase domain bind to the resin, but SBD does not (Figure 1B).
To further demonstrate that Az binds selectively to the ATPase
domain of HSP70, ATP-agarose was incubated with the full-
length protein and the ATPase domain in the absence and
presence of 100 mM Az or 1 mM ATP as a competitor. Whereas
both proteins bind to the ATP-resin in the absence of Az and
ATP, addition of each of these substances leads to a marked
decrease in binding of the proteins to ATP-agarose (Figure 1C).
Next, the ability of Az to inhibit the ATPase activity of HSP70
was evaluated. The results of a malachite green assay (Cho
et al., 2011), which is used to determine monophosphate
released from ATP, show that Az inhibits the ATPase activity of
HSP70 by 32% at 100 mM and 65% at 200 mM in the presence
of 200 mM ATP (Figure S1B).
To examine whether Az binds to other types of heat shock pro-
teins, purified HSP90, HSP70, and HSP40 (Figure S1A) were
individually incubated with an Az-linked resin in the absence
and presence of Az (50 or 100 mM). As the results in Figure 1D
show, while HSP70 binds to the Az-linked resin, HSP90 and
HSP40 do not. In addition, we incubated the Az-linked resin
with HeLa cell lysates in the absence and presence of Az (50
or 100 mM). The results of affinity chromatography show that
HSP60 and HSP90 do not bind to the Az-linked resin (Figure 1E).
Taken together, the observations indicate that Az inhibits the
ATPase activity of HSP70 by binding to its ATPase domain and
that it does not bind to other types of heat shock proteins.
Binding Mode of Az to HSP70
To gain an understanding of the binding mode of Az to HSP70,
nuclear magnetic resonance (NMR) and molecular modeling
studies were performed. Saturation transfer difference (STD)
NMR is a popular ligand-based NMR method used to probe
ligand-protein interactions at atomic resolution (Meyer and Pe-
ters, 2003; Viegas et al., 2011). In particular, this NMR technique
provides ligand-specific binding information. A sample contain-
ing 10 mM ATPase domain of HSP70 and 1 mM Az in 20 mM of
deuterated Tris buffer (pD 7.0) was found to display a reproduc-
ible and well-resolved spectrum. The results of STD NMR data
analysis show that all the benzene ring protons of Az (H7, H8,
H10, H11, H13, H14, H16, and H17) display large STDs (Figures
S2A and S2B), suggesting that they are positioned in close
proximity to the binding site of the protein. However, the H1–
H6 and H9 protons show only a small level of saturation, sug-
gesting that they only slightly contribute to binding to the pro-
tein. These results provide evidence to support the proposal
that Az binds to the ATPase domain of HSP70 presumably
through interactions of its aromatic rings with residues in the
protein binding site.
Two-dimensional (2D) 1H-1H NOESY NMR experiments were
conducted to gain information about the conformation of un-
bound Az. The NMR data yielded a range of conformations of
this substance (Figures S2C and S2D), which were then sub-
jected to computational analysis to elucidate the low energy
conformation of free Az (Figure S2E). The conformational infor-
mation and STD NMR data were utilized for molecular docking
studies with HSP70 (PDB code 4IO8, a VER-155008 complex
form; and PDB code 2E8A, an AMP-PNP [adenylyl-imidodiphos-
phate, a non-hydrolyzable analog of ATP] bound form) to obtain
a more detailed view of the binding mode of Az to HSP70 (Cho
et al., 2011; Schlecht et al., 2013; Shida et al., 2010). The results
of a molecular modeling study show that Az adopts a conforma-
tion that is closely overlaid with AMP-PNP in the ATP binding site
of HSP70 (Figure 2A). Specifically, the 3,5-bis(trifluoromethyl)Chemistry & Biology 22, 3phenyl group of Az interacts with residues in the site that bind
to the phosphate moiety of AMP-PNP through polar interactions
(Muller et al., 2007), and the 4-methoxyphenyl moiety at the R2
position of Az is positioned in the adenine binding site of the pro-
tein where it interacts with the side chain of Ser275 via hydrogen
bonding. On the other hand, the 4-methoxyphenyl group at R3 in
Az interacts with the side chain of Arg272 via the cation-p inter-
action and a benzyl group in Az via thep-p interaction. The com-
bined results suggest that Az binds to the ATP binding site of
HSP70 in a manner similar to that previously observed for its
binding to HSC70, which has a high sequence and structural
homology with HSP70 (Cho et al., 2011).
In an effort to understand the structural features responsible
for inhibition of the ATPase activity of HSP70 by Az, 15 members
(1–15) of a focused imidazole library were prepared using solid
support and solution-based methods (Figure 2B) (Kim et al.,
2014; Williams et al., 2007, 2008a, 2008b). Effects of the Az
analogs on inhibition of the ATPase activity of HSP70 were
evaluated using a malachite green assay (Figure 2C). The results
show that 1 and 4, which contain two electron withdrawing
groups (CF3 or CO2Me) on a phenyl group at R1, display higher
inhibitory activities than analogs with electron donating (5–7) or
single electron withdrawing groups (2, 3). This finding suggests
that the R1 moiety of Az is likely located at the binding site of a
phosphate moiety of ATP in HSP70 for polar interactions (vide
supra).
Imidazole derivatives 8 and 9, in which 4-methoxy groups
present at R2 and R3 positions in Az are replaced by electron
withdrawing groups (Cl or Br), display lower inhibitory activities
than Az or 10, which possesses electron donating 4-methyl
groups. This phenomenon could be explained by the reduced
cation-p interaction between an R3 moiety and the side chain
of Arg272. However, a derivative 11with 4-dimethylaminophenyl
groups at these positions exhibits a lower inhibitory activity than
Az, a possible result of steric hindrance between R2 and the
binding site of the protein. This proposal is supported by the
observation that 12–14 containing large fused aromatic rings at
R2 have low inhibitory activities. When the NH(CH2)2O(CH2)2NH2
moiety in Az is replaced by NH2 (see 15), the inhibitory activity is
slightly attenuated, suggesting that NH(CH2)2O(CH2)2NH2 is
involved in the interaction of Az with the protein to a certain
extent, as shown in STDNMRdata. Overall, Az displays the high-
est ATPase inhibitory activity among the tested compounds.
Furthermore, this structure-activity relationship study suggests
that although the size and position of substituents attached to
phenyl rings in Az affect binding to HSP70, incorporation of elec-
tron withdrawing groups at R1 and electron donating groups
at R2 and R3 are required to sustain inhibitory activity toward
HSP70.
Az Induces Apoptosis in Cancer Cells
Previous studies have served to show that HSP70 acts as an anti-
apoptotic protein to promote cancer cell survival (Powers and
Workman, 2007). To investigate the effect of Az on cancer cell
viability, several cancer cell lines (A549, lung adenocarcinoma
epithelial cells; HeLa, cervical cancer cells;MDA-MB-231, breast
cancer cells; HepG2, liver cancer cells) were treated with various
concentrations (0–15 mM) of Az or compound 7 as a negative
control for 18 hr. Cell viabilities were then determined using91–403, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 393
Figure 2. Structure-Activity Relationships
(A) (Left) Docking model of Az (green)/HSP70 superimposed on AMP-PNP (blue, adenosine; orange, b,g-imidotriphosphate). Red and cyan arrows denote in-
tramolecular p-p stacking and intermolecular cation-p interactions, respectively. (Right) An electrostatic potential surface of the Az binding site of HSP70. Red
shows regions of negative charge and blue denotes regions of positive charge.
(B) Structure of Az derivatives 1–15.
(C) Inhibition of ATPase activity of an ATPase domain of HSP70 by the analogs. ATPase activities were measured using a malachite assay after incubation of an
ATPase domain with 100 mM of each compound and 50 mM ATP (mean ± SD).an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay. The number of viable cells was found to
decrease in an Az dose-dependent way with half maximal inhib-
itory concentration (IC50) values that ranged from5 to 7mM,unlike
compound 7 which did not show cytotoxicity (Figures S3A and
S3D). In addition, when the incubation times of Azwere extended
to 48 and 72 hr before conducting theMTT assay, the IC50 values
were observed to decrease to the nanomolar range (0.9–1.0 mM
for 48 hr and 0.7–0.8 mM for 72 hr) (Figures S3B and S3C).394 Chemistry & Biology 22, 391–403, March 19, 2015 ª2015 ElsevieThe MTT assay is a widely used method for the measurement
of cell death, although it does not discriminate between
apoptosis and necrosis. To elucidate whether Az induces can-
cer cell death via apoptosis, A549 cells were incubated with
8 mM Az for 18 hr and then treated with a mixture of fluores-
cein-annexin V and propidium iodide (PI). The results of flow cy-
tometry analysis show that Az induces apoptosis, as inferred
from the observation of positive annexin V binding and PI up-
take, characteristic features of late apoptosis (Figure 3A) (Kor Ltd All rights reserved
Figure 3. Az Induces Apoptosis
Untreated cells are shown as a negative control.
(A) Flow cytometry of A549 cells treated with 8 mM
Az for 18 hr and then stained with a mixture of
FITC-annexin V and PI (annexin V versus PI up-
take).
(B) A549 cells were treated with 8 mM Az for 18 hr.
Cell size was determined using flow cytometry.
(C) Flow cytometry of A549 cells treated with 8 mM
Az for 18 hr and then stained with JC-1. A dot plot
of green fluorescence (FL1, JC-1 monomer)
versus red fluorescence (FL2, JC-1 aggregate) is
shown.et al., 2014). Analysis of cell size by flow cytometry revealed that
Az-treated cells exhibit a large degree of cell shrinkage (Fig-
ure 3B). Because cell death via necrosis induces cell swelling,
this observation serves as additional evidence to support the
proposal that the treated cells undergo apoptosis. The loss of
mitochondrial membrane potential, a hallmark of apoptosis,
was also examined using a JC-1 probe that is sensitive to mem-
brane potential (Smiley et al., 1991). The intensity of dye derivedChemistry & Biology 22, 391–403, March 19, 2015red fluorescence in cells treated with
8 mM Az for 18 hr was found to decrease
markedly, as is expected for apoptotic
cell death (Figure 3C). Moreover, other
typical apoptotic phenotypes, such as
loss of cell adherence, condensed cyto-
plasm, and apoptotic bodies, are also
observed microscopically in the Az-
treated cells. The combined results
provide clear evidence that Az has
apoptosis-inducing activity.
AzDoesNotDisrupt Associations of
HSP70 with ASK1, JNK, and BAX
An investigation was conducted to gain
additional information about the cellular
mechanism by which inhibition of the
ATPase activity of HSP70 by Az pro-
motes apoptosis. ASK1 is known to be
activated under various stress conditions
to induce apoptotic cell death (Park
et al., 2001; Tobiume et al., 2001).
HSP70 suppresses apoptosis by inhibit-
ing ASK1 activation through the physical
interaction of its ATPase domain with
ASK1 in an ATP-independent manner
(Figure S4A) (Park et al., 2002). It
has been also reported that HSP70
suppresses apoptosis by inhibiting
both JNK activation and JNK-mediated
apoptosis through direct binding of its
SBD to JNK, independent of the chap-
erone activity of HSP70 (Smiley et al.,
1991; Yaglom et al., 1999). In addition,
it is known that the translocation of the
proapoptotic protein BAX to the mito-chondria induces apoptotic cell death (Gotoh et al., 2004).
Although not yet thoroughly studied, this process is suppressed
by direct binding of HSP70 to BAX in which the ATPase domain
of HSP70 is necessary.
Based on these observations, the question of whether or not
Az interferes with interactions of HSP70 with ASK1, JNK, and
BAX during Az-induced apoptosis was explored. For this pur-
pose, HeLa cells were treated with 5 or 10 mM Az for 18 hr,ª2015 Elsevier Ltd All rights reserved 395
Figure 4. Az Does Not Affect Binding of HSP70 to ASK1, JNK, and BAX
HeLa cells were treated with Az for 18 hr. Immunoprecipitation was performed with (A) ASK1, (B) JNK (C) BAX, and (D) HSP70 antibodies, and the amount of
HSP70, ASK1, JNK, and BAX co-precipitated with each protein was determined by western blot.after which ASK1 and JNK were immunoprecipitated using the
corresponding antibodies. Endogenous HSP70 in co-immuno-
precipitated complexes of HSP70 with ASK1 or JNK was de-
tected by western blot analysis. The results show that Az
neither blocks the association of HSP70 with ASK1 and JNK
nor does it affect the expression levels of HSP70, ASK1, and
JNK (Figures 4A, 4B, and 4D). The effects of Az on the activa-
tion of ASK1 and JNK were also examined by evaluating the
levels of their phosphorylated forms in treated cells. The
results of immunoblot analysis show that Az treatment does
not lead to production of phosphorylated ASK1 and JNK
(Figure S5A).
Next, to evaluate the effect of Az on the association of HSP70
with BAX, we determined the amount of BAX co-immunoprecip-
itated with HSP70 that was produced after HeLa cells were
treated with 5 or 10 mM Az for 18 hr. The results show that the
expression level of BAX and the amount of HSP70 interacting
with BAX remain unchanged in the treated cells (Figures 4C
and 4D). Because it is not known which domain of HSP70 inter-
acts with BAX, we investigated this by incubating HeLa cell ly-
sates with purified full-length or truncated (ATPase domain and
SBD) HSP70. Immunoblot analysis shows that BAX binds to
both full-length and the ATPase domain of HSP70 irrespective
of the presence of Az, but does not interact with the SBD (Fig-
ure S5B). The results indicate that BAX binds to the ATPase
domain of HSP70 but that ATPase activity of HSP70 is not
required for this binding. Taken together, the results show that
Az does not block interactions of HSP70 with ASK1, JNK, and
BAX, and that the ATPase activity of HSP70 is not essential for
these interactions.396 Chemistry & Biology 22, 391–403, March 19, 2015 ª2015 ElsevieAz Does Not Induce AIF-Mediated Caspase-
Independent Apoptosis
HSP70 has been known to directly interact with AIF to suppress
its translocation to the nucleus, thus leading to blockage of cas-
pase-independent apoptosis (Figure S4) (Beere et al., 2000;
Ravagnan et al., 2001; Susin et al., 1999). Because of this phe-
nomenon, we determined whether Az blocks the association of
HSP70 with AIF to induce cell death via caspase-independent
apoptosis. HeLa cells were treated with 5 or 10 mM Az for
18 hr, after which AIF or HSP70was immunoprecipitated. The re-
sults of probing these precipitates using each antibody show
that the amount of HSP70 bound to AIF is not changed by treat-
ment of the cells with Az (Figure 5A). In addition, observations
made in immunocytochemical analysis indicate that treatment
with Az does not induce AIF translocation to the nucleus (Fig-
ure 5B). Because Az inhibits the ATPase activity of HSP70, which
is not required for the interaction with AIF (Ravagnan et al., 2001),
this substance does not influence HSP70 binding to AIF and,
consequently, it does not induce cell death via AIF-mediated,
caspase-independent apoptosis.
Az Blocks Association of HSP70 with APAF-1
Several studies have served to demonstrate that HSP70 halts
progression of the caspase-dependent apoptotic pathway by
direct binding of SBD of HSP70 to APAF-1 (Beere et al., 2000;
Saleh et al., 2000). To examine whether Az induces caspase-
dependent apoptosis by blocking the association of HSP70
with APAF-1, HeLa cells were treated with 5 or 10 mMAz or com-
pound 7 as a negative control for 18 hr, after which cell lysates
were immunoisolated using HSP70 and APAF-1 antibodies.r Ltd All rights reserved
Figure 5. Az Does Not Interfere with Inter-
action of HSP70 with AIF but Blocks
HSP70 Binding to APAF-1
(A) HeLa cells were treated with Az for 18 hr,
and immunoprecipitation performed with AIF or
HSP70 antibody. The amount of co-precipitated
HSP70 or AIF was determined by western blot.
(B) HeLa cells were treated with 6 mM Az for 6
and 18 hr, and processed for immunofluorescence
microscopy. Cells were immunostained with AIF
antibody and nuclei were visualized with DAPI.
Scale bar, 20 mm.
(C) HeLa cells were treated with Az for 18 hr, and
indicated proteins were immunoblotted with the
corresponding antibodies.
(D) HeLa cells were treated with Az for 18 hr, and
immunoprecipitation performed with HSP70 or
APAF-1 antibody. The amount of co-precipitated
APAF-1 or HSP70 was determined by western
blot.The results of immunoblot analysis demonstrate that treatment
with increasing amounts of Az leads to a gradual decrease in
the amount of APAF-1 associated with HSP70 without affecting
the expression level of APAF-1 (Figures 5C and 5D). However,
compound 7 did not affect the association of HSP70 with
APAF-1 (Figure S5C). If caspase-dependent apoptosis takes
place in Az-treated cells, APAF-1 should activate procaspase-
9 to generate a proteolytically cleaved caspase-9 (Beere et al.,
2000; Saleh et al., 2000). The results of western blot analysis
show that cleaved procaspase-9 is produced in the treated cells
(Figure 5C).
To exclude the possibility that Az has off-target effects, HeLa
cells were transfected with an HSP70 overexpression vector or
an empty vector as a control and then treated with 5 or 10 mM
Az for 18 hr. Compared with the control transfected with empty
vector, HSP70-transfected cells were found to contain signifi-
cantly elevated levels of HSP70 (Figure S5D). The results of
immunoprecipitation analysis show that the amount of APAF-1
bound to HSP70 is nearly unchanged in HSP70-transfected cells
treated with Az (Figure S5D), indicating that HSP70 is the cellular
target of Az. Since the ATPase activity of HSP70 is essential forChemistry & Biology 22, 391–403, March 19, 2015association with APAF-1(Ravagnan et al.,
2001), Az prevents this interaction and in-
duces caspase-dependent apoptosis.
Az Induces Caspase Activation
To gain further support for the proposition
that Az induces cell death via caspase-
dependent apoptosis, the effect of this
substance on caspase activation was
investigated by measuring proteolytic
activities associated with caspases. The
activities of caspases in lysates of HeLa
cells treated with various concentrations
(0–10 mM) of Az for 18 hr were measured
using the colorimetric assay with the pep-
tide substrate, Ac-DEVD-pNA (pNA, p-ni-
troaniline). Increases in caspase activitywere observed to take place in an Az concentration-dependent
manner (Figure S5E). However, when Ac-DEAD-CHO, a known
inhibitor of caspases, was added to the lysates of cells treated
with Az, caspase activities were greatly attenuated.
As APAF-1 activation and subsequent caspase-9 activation
lead to the cleavage of procaspase-3 to produce active cas-
pase-3 (Li et al., 1997), we examined caspase-3 activation by
incubating A549 and HeLa cells with 5 or 10 mM Az for 18 hr.
Immunoblot analysis reveals that procaspase-3 is proteolytically
cleaved to generate caspase-3 (Figure S5F). The results of addi-
tional experiments aimed at detecting cleavage of the endoge-
nous caspase substrate, PARP, by western blot analysis show
that the cleavage product of PARP is produced in Az-treated
cells. However, activation of caspase-3 and cleavage of PARP
do not take place to appreciable extents in HSP70-transfected
cells treated with Az (Figure S5G), indicating that this small mole-
cule induces caspase activation by inhibiting HSP70 activity.
Next, we evaluated whether the pan-caspase inhibitor ZVAD-
FMK (benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethylke-
tone), which is a cell-permeable, irreversible caspase inhibitor
with broad specificity (Nicholson et al., 1995), protected cellsª2015 Elsevier Ltd All rights reserved 397
Figure 6. Combined Effect of Az with Dox on Cell Death
(A) A549 cells were treated with Dox alone or a combination of Dox and Az for
12 hr. Cell viabilities were measured using the MTT assay (mean ± SD).
(B) A549 cells were treated with Dox in the presence and absence of 2 mM Az
for 12 hr. Activated caspase-3 expression, PARP cleavage, and HSC70 and
HSP70 expression levels were determined by western blot.against the effect of Az. For this purpose HeLa cells, pre-treated
with 20 or 40 mM ZVAD-FMK for 3 hr, were incubated with
various concentrations (0–8 mM) of Az for 18 hr. Under these con-
ditions the cells were greatly protected from apoptotic cell death
induced by Az (Figure S5H). The results of western blot analysis
provide further evidence that caspase activation induced by Az
is blocked by treatment with 20 mM of the inhibitor (Figure S5I).
Taken together, these observations demonstrate that Az-
induced cell death occurs via caspase-dependent apoptosis.
Combined Treatment of Az and Doxorubicin Enhances
Apoptosis of Cancer Cells
It has been reported that HSP70 renders cells resistant to
chemotherapy, and that the overexpression of HSP70 protects
cancer cells from antitumor agents such as doxorubicin (Dox)
(Demidenko et al., 2006). Thus, it is possible that treatment of
cancer cells with a combination of a HSP70 inhibitor and Dox
would enhance cancer cell death in comparison with treatment
with only one of these substances. To test this proposal, A549
and HeLa cells were co-incubated with Az (0–3 mM) and Dox
(0–8.6 mM) for 12 hr. Cell viabilities were then determined using
an MTT assay. The results show that the effect of the combined
treatment on cell death is more profound than that promoted by
Dox alone (Figures 6A and S6A). In both A549 and HeLa cells,398 Chemistry & Biology 22, 391–403, March 19, 2015 ª2015 ElsevieIC50 values of Dox in the presence of 3 mM Az are approximately
half those of Dox alone (2.6 mM of IC50 of Dox at 0 mM Az versus
1.0 mM of IC50 at 3 mM Az for A549 cells; 3.5 mM of IC50 of Dox at
0 mM Az versus 1.7 mM of IC50 at 3 mM Az for HeLa cells). Immu-
noblot analysis revealed that caspase-3 activation and PARP
cleavage occur in cells treated with a combination of Az and
Dox (Figures 6B and S6B). These findings show that inhibition
of HSP70 by Az may be especially powerful in combination
with other chemotherapeutic agents for cancer treatment.
Az Inhibits Tumor Growth in Mouse Models
Wenext turned our attention to an assessment of the therapeutic
potential of Az in vivo. For this purpose, the pharmacokinetic
properties of Az were examined using a mouse model, adminis-
tering the substance (10 mg/kg) by an intraperitoneal route. The
values of the parameters were compared with those obtained af-
ter intraperitoneal injection of Dox into rat (Reddy and Murthy,
2004). The elimination half-life time (T1/2) of Az in blood was
found to be significantly longer than that of Dox (8.04 versus
1.60 hr) and the time needed to reach a maximum concentration
(Tmax) of Az was shorter than that of Dox (1.00 versus 4.00 hr)
(Figure S7A; Table S1). These findings indicate that Az appears
more rapidly and is present for a longer time in blood than is
Dox after injection.
The efficacy of Az in the nude mice xenografted with A549,
RKO (colorectal carcinoma), and HeLa cells was assessed
next. Az was injected intraperitoneally at 4 mg/kg every other
day for 2 weeks. The sizes of the A549, RKO, and HeLa xeno-
grafts, measured over a 30-day period, were found to be smaller
in mice treated with Az than in mice treated with the vehicle (Fig-
ure 7A). Specifically, compared with the vehicle-treated group,
61%, 65%, and 68% volume reductions of the respective
A549, RKO, and HeLa xenografts took place in Az-treated mice.
The antitumor effect of a combination of Az and Dox was also
examined in the nude mice xenografted with HeLa cells. The re-
sults reveal that treatment with both Az and Dox ismore effective
in reducing tumor volume in mice than treatment with either
agent alone. Specifically, 68%, 61%, and 81% reductions in
tumor volumes occur in mice treated with Az and Dox indepen-
dently, and a combination of Az and Dox, respectively,
compared with those of a vehicle-treated group (Figure 7A).
Importantly, no significant loss of body weight takes place in
mice treated with Az or a combination of Az and Dox (Figures
S7B–S7D). In addition, diarrhea- and treatment-related death
was not observed in the Az-treated group.
To evaluate Az-induced apoptosis of cancer cells in mice,
terminal deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate nick end-labeling (TUNEL) values were determined
as the ratio of TUNEL-positive cells to total cell numbers in tumor
xenografts (Gavrieli et al., 1992). In the absence of Az treatment,
the number of TUNEL-positive cells was found to be less than
7% (Figure 7B). However, Az treatment causes a significant in-
crease in TUNEL-positive cells in mice. The number of apoptotic
cells in Az-treatedmice is more than 40% in themice bearing the
A549, RKO, and HeLa cells. Importantly, combined treatment
with Az and Dox leads to apoptosis in 81% of the tumor cells,
whereas Az or Dox alone induces apoptosis in 41% and 26%
of the tumor cells, respectively. The observations made in the
animal model studies provide evidence that Az effectively killsr Ltd All rights reserved
Figure 7. Effect of Az on a Tumor-Xenografted Mouse Model
(A) Effect of Az treatment on the growth of tumor xenografts in nude mice (n = 10). Az was injected intraperitoneally into mice at 4 mg/kg/day every other day for
2 weeks and tumor volumes were determined every 3 days over a 30-day period after Az injection.
(B) A TUNEL assay was performed to evaluate Az-induced apoptosis of tumor xenografts in mice. (Left) Fluorescence images of vehicle, Az-, Dox-, and Az + Dox-
treated tumors in mice (red, TUNEL; blue, DAPI). Scale bar, 10 mm. (Right) The bar graphs show the percentage of TUNEL-positive nuclei relative to the total
number of nuclei in each section (mean ± SD, *P < 0.01).cancer cells in mice via the apoptotic process and that the effect
of Az is enhanced when it is used in combination with Dox.
DISCUSSION
It is known that the expression level of HSP70 is markedly
increased in various cancers, and this upregulation leads to the
survival of cancer cells via multiple antiapoptotic processes.
High levels of HSP70 are associated with tumor development,
resistance to chemotherapy, and poor prognosis in cancer. AsChemistry & Biology 22, 3a consequence, HSP70 has become a highly attractive target
for cancer chemotherapy. This study demonstrates that Az binds
to HSP70 but not to other heat shock proteins such as HSP40,
HSP60, and HSP90, suggesting that Az is able to overcome the
selectivity limitation of HSP70 inhibitors. The results of STD
NMR and molecular docking studies suggest that Az binds to
an ATP binding site of HSP70 and, as a result, inhibits ATPase
activity of the protein. The findings of mechanistic studies in cells
reveal that Az blocks binding of HSP70 to APAF-1 without
affecting its binding to ASK1, JNK, BAX, and AIF, indicating91–403, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 399
that Az induces cancer cell death via caspase-dependent
apoptosis (Figure S4). Our results demonstrate that inhibition of
ATPase activity of HSP70 is enough to sensitize cancer cells to
apoptosis. In mouse studies, we have also observed that admin-
istration of Az leads to a marked retardation of tumor growth and
an increase in the number of apoptotic cells. More interesting is
the finding that combined treatment with Az and Dox induces a
greater antiapoptotic activity in cancer cells and antitumor activ-
ity in tumor xenografts than that promoted by treatment with
either agent alone. This result indicates that Az could play a
unique role in anticancer therapy through its use in combination
with existing chemotherapeutics to reduce required doses and,
consequently, toxic side effects. It has been reported that simul-
taneous reduction of the expression of both HSP70 and HSC70
with siRNA induces apoptosis of cancer cells but does not result
in induction of apoptosis in non-tumorigenic cells (Powers et al.,
2008). Because Az suppresses ATPase activities of both HSP70
andHSC70, it has good antitumor activity without side effects, as
shown in our animal model study. It is expected that Az could aid
the development of new cancer chemotherapies and serve as a
chemical probe in studies aimed at gaining a better understand-
ing of the diverse functions of HSP70.
SIGNIFICANCE
The chaperone protein HSP70 acts as an antiapoptotic factor
to protect cells from various apoptotic stresses. This protein
is upregulated inmany cancer types and its overexpression is
associated with tumor development, increased resistance to
chemotherapy, and poor prognosis. Therefore, small mole-
cule inhibitors of HSP70 have received great attention as
potent anticancer agents. We have investigated whether our
small molecule, Az, which inhibits the ATPase activity of
HSP70 by binding to its ATPase domain, is sufficient for
inducing cancer cell death via apoptosis. Initial affinity chro-
matography study shows that Az binds HSP70 but not other
types of heat shock proteins, indicating that Az has selective
inhibitory activity toward HSP70. We have demonstrated that
an inhibitor of ATPase activity of HSP70 indeed induces an
array of apoptotic phenotypes in cancer cells. We have also
examined whether this substance induces cancer cell death
via caspase-dependent or -independent apoptosis, or both.
Our results show that Az induces caspase-dependent
apoptosis by blocking the interaction of HSP70 with APAF-1,




with Dox in cells and mouse. The present investigation could
aid the development of novel cancer chemotherapies.
EXPERIMENTAL PROCEDURES
Synthesis of Apoptozole Derivatives
Compounds 1–15 were prepared according to a known procedure (Cho et al.,
2015).
NMR Study
NMR spectra were recorded on an Agilent DD2 600-MHz NMR spectrometer
equipped with a TR probe at 298 K. The one-dimensional STD NMR data were400 Chemistry & Biology 22, 391–403, March 19, 2015 ª2015 Elseviecollected using a 2-s transfer delay and 1,024 scans. On-resonance irradiation
of a mixture of Az and protein was set at 1.0 ppm, and off-resonance irradi-
ation at 31.6 ppm. The protons in the spectrum of Az were unambiguously as-
signed using 2D COSY and 2D NOESY NMR data and inter-proton distances
were determined from normalized cross-peak volumes in the 2D NOESY NMR
spectrum. A sample containing 1mMAz (a phosphate salt, formed bymixing 1
equivalent Az and 2 equivalent phosphoric acid) and 10 mM ATPase
domain of HSP70 was prepared in deuterated Tris buffer (pD 7.0) for NMR
measurements.
Molecular Modeling
The crystal structure of HSP70 from the PDB (code 4IO8, a VER-155008 bound
form) was used for docking simulations. The structure of Az was built using the
Maestro build panel and minimized using the Impact module of Maestro in the
Schro¨dinger suite program. The starting coordinates of HSP70 were further
modified for Glide docking. The HSP70/VER-155008 complex was imported
to Maestro and the ligand was removed from the structure. Water molecules
were removed and hydrogen atoms were added to the crystal structure of
HSP70. The protein structure was minimized using the Protein Preparation
Wizard by applying an OPLS (optimized potentials for liquid simulations) force
field. For grid generation, the binding site was defined as the centroid of the
VER-155008. Ligand docking into the ATP binding site of HSP70 was carried
out using the Schro¨dinger docking program, Glide. Energy minimized Az was
docked into the prepared receptor grid. The best-docked pose was selected
as the lowest Glide score. Molecular graphics for the inhibitor binding pocket
and refined dockingmodel for the selected Azwere generated using the PyMol
package (http://www.pymol.org).
Cell Culture
The A549 (lung cancer cells), HeLa (cervical cancer cells), MDA-MB-231
(breast cancer cells), and HepG2 (liver cancer cells) cells were obtained from
the American Type Culture Collection and grown in RPMI 1640 (Invitrogen)
supplemented with 10% fetal bovine serum (FBS), 50 units/ml penicillin, and
50 units/ml streptomycin. Cells were maintained at 37C under a humidified
atmosphere of 5% CO2.
Affinity Chromatography Using Az-Linked and ATP Resins
Az-linked resin or ATP-agarose (Sigma-Aldrich) in bead buffer (10 mM Tris [pH
7.4], 5 mM NaF, 250 mM NaCl, 5 mM EDTA, 5 mM EGTA, 0.1% Triton X-100,
and one tablet of protease inhibitor cocktail [Roche] per 20ml buffer) was incu-
bated with 2–5 mg of purified proteins (full-length and truncated HSP70,
HSP40, and HSP90) at 4C for 1 hr. In competition experiments, 100 mM Az
or 1 mM ATP was added to each protein in bead buffer, and the mixture
was incubated at 4C for 30 min. Az-linked resin or ATP-agarose was incu-
bated with the protein pre-treated with the competitor and washed several
times with 1 ml of bead buffer. Proteins bound to the resin were collected
with 30 ml of Laemmli buffer (Bio-Rad) at 94C for 5 min and separated using
10% SDS-PAGE for silver staining and western blot analysis.
Measurements of ATPase Activities of HSP70
A master mix of an ATPase domain of HSP70 (final concentration 2 mM) was
prepared in assay buffer (100 mM Tris-HCl, 20 mM KCl, and 6 mM MgCl2
[pH 7.4]). An aliquot (10 ml) of this mixture and 9 ml of Az in assay buffer were
added to a 96-well plate and incubated for 30 min at room temperature. The
reaction was started by adding 1 ml of 4 mM ATP. After 3 hr of incubation at
37C, 80 ml of malachite green reagent was added to each well and was incu-
bated at 37C for 15min, and 10 ml of 34% sodiumcitrate was added to halt the
non-enzymatic hydrolysis of ATP. The absorbance was determined at 620 nm
with a SpectraMax 340 PC 384 (Molecular Devices). To correct for non-enzy-
matic hydrolysis of ATP, the absorbance of a sample formed from an identi-
cally treated ATP buffer lacking the protein was subtracted.
MTT Assay
Cells (5 3 103 per well) were plated in triplicate in 96-well plates in 0.1 ml of
culture media with 10% FBS. After 24 hr, cells were treated with various con-
centrations of Az (0–15 mM) in culture media with 3% FBS (final volume: 0.2 ml
per well) for 18, 48, and 72 hr before treatment with MTT. MTT assays were
performed according to general procedures. Absorbance at 570 nm wasr Ltd All rights reserved
measured using a UV microplate reader (SpectraMax 340PC 384; Molecular
Devices).
Western Blot Analysis
Proteins were separated by 6%–12% SDS-PAGE. Mouse HSP60 monoclonal
(1:1000, Santa Cruz Biotechnology), mouse HSP70 monoclonal (1:1000,
StressGen Biotechnology), mouse HSP90 monoclonal (1:1000, Santa Cruz
Biotechnology), rabbit caspase-9 polyclonal (1:1000, Santa Cruz Biotech-
nology),mouseprocaspase-3monoclonal (1:1000,SantaCruzBiotechnology),
rabbit cleaved caspase-3 polyclonal (1:1000, Santa Cruz Biotechnology), rab-
bit PARP polyclonal (1:1000, Cell Signaling Technology), rabbit AIF polyclonal
(1:1000, Santa Cruz Biotechnology), rabbit BAX polyclonal (1:1000, Santa Cruz
Biotechnology), rabbit JNK polyclonal (1:1000, Santa Cruz Biotechnology),
rabbit ASK1 polyclonal (1:1000, Santa Cruz Biotechnology), and mouse
APAF-1 monoclonal (1:1000, Santa Cruz Biotechnology) antibodies were
used as primary antibodies. Horse peroxidase-conjugated goat anti-mouse
immunoglobulin G (IgG) (1:5000, Sigma-Aldrich) was used as the secondary
antibody, and the treatedmembranes were visualized using the ECL kit (Amer-
sham Biosciences). Quantitative data were obtained with ImageQuant version
5.2 (Molecular Dynamics) and Origin version 8.0 (Microcal).
Immunocytochemistry
HeLa cells pre-incubated with Az were fixed with 4% formaldehyde in PBS
buffer for 15 min and processed for immunostaining. The cells were incubated
with rabbit AIF polyclonal antibody (1:200, Santa Cruz Biotechnology) for 1 hr
at room temperature followed by incubation with Alexa-Fluor 488 conjugated
rabbit IgG (1:200, Invitrogen/Molecular Probes) for 0.5–1 hr at room tempera-
ture and mounted with DAPI (Invitrogen/Molecular Probes). The cells were
imaged by confocal fluorescence microscopy (Zeiss).
Flow Cytometry
A549 cells were treated with 8 mM Az for 18 hr. Untreated cells were used as a
negative control. After washing with PBS twice, the cells were incubated with
0.5 ml of trypsin-EDTA (0.05% trypsin, 0.02% EDTA; Sigma-Aldrich) for 5–
10 min at 37C and collected. Cells were re-suspended in binding buffer
(500 ml, 10 mM HEPES/NaOH [pH 7.5] containing 1.4 M NaCl and 2.5 mM
CaCl2) and treated with a mixture of fluorescein-annexin V (final concentration
0.5 mg/ml) and PI (final concentration 2 mg/ml) for 10 min at room temperature.
For JC-1 staining, cells were re-suspended with PBS containing JC-1 (final
concentration 2.5 mg/ml; Anaspec), incubated for 15 min, and washed with
PBS twice. Flow cytometry was performed using FACSCalibur (BD Biosci-
ences) and CellQuest software (Becton Dickinson). The red fluorescence
signal was measured using excitation wavelength of 550 nm and emission
wavelength of 600 nm, and the green fluorescence using 485-nm excitation
and 535-nm emission.
Caspase Activity Assay
Caspase activity was determined using acetyl-DEVD-pNA (Sigma-Aldrich), a
preferred substrate for caspase-3 and -7. The enzyme-catalyzed release of
pNA was monitored at 405 nm using a UV microplate reader.
Immunoprecipitation
HeLa cells were treated with 5–10 mM Az for 18 hr in parallel with an untreated
negative control. Cells were lysed with 13 RIPA buffer (50 mM Tris-HCl [pH 8],
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and one tablet of pro-
tease inhibitor cocktail) for 10 min at 4C and centrifuged at 10,000 rpm for
10 min. Cell lysates were pre-cleared with 20 ml of the appropriate suspended
(25%, v/v) agarose conjugate (protein A-agarose or protein G-agarose, Invitro-
gen) for 30min at 4C and incubated with primary antibodies for 2 hr at 4C. To
capture antibody on the resin, antibody-treated lysates were incubated with
protein A-agarose or protein G-agarose on the rotator at 4C overnight. Immu-
noprecipitates were collected and analyzed by western blots.
Antitumor Activity in Mouse
Male nudemice were purchased fromOrient Bio Co. The animals were housed
in a pathogen-free room under controlled temperature and humidity. The
animal study was conducted according to the established procedures of the
Yonsei University Laboratory Animal MaintenanceManual. Mice aged 4weeksChemistry & Biology 22, 3were injected with tumor cells for the xenograft experiments. Viable A549 and
RKO cells (53 106) and HeLa cells (53 106) were injected subcutaneously into
the flank ofmice. The A549 and RKO cell xenograft micewere immediately and
randomly assigned to two groups. The first group (n = 10) was used as a con-
trol group and received vehicle only. The second group (n = 10) received intra-
peritoneal injections of Az (4mg/kg/day) every other day for 2 weeks. The HeLa
cell xenograft mice were immediately and randomly assigned to four groups.
The first group (n = 10) was a control group receiving vehicle only. The second
group (n = 10) received intraperitoneal injections of Az (4 mg/kg/day) every
other day for 2 weeks. The third group (n = 10) received intraperitoneal injec-
tions of doxorubicin (15 mg/kg/day) every other day for 2 weeks. The fourth
group (n = 10) received intraperitoneal injections of Az (4 mg/kg/day) and
doxorubicin (15 mg/kg/day) every other day for 2 weeks. Tumors in all mice
were measured in two dimensions with calipers every 3 days and tumor vol-
umes were calculated using the formula volume = w 3 l2/2, where w is the
width at the widest point of the tumor and l is the length perpendicular to w.
The results from individual mice were plotted as average tumor volumes
versus time.
Combined Treatment of Apoptozole and Doxorubicin
A549 and HeLa cells were plated in triplicate in 0.1 ml in 96-well plates for 24 hr
and treated with various concentrations of doxorubicin alone or a combination
of doxorubicin (0.8–8.6 mM) with Az (2 or 3 mM). After 12 hr, cells were analyzed
by the MTT assay and western blots as described above.
Statistical Analysis
All data are reported as means ± SD. Statistical significance of differences be-
tween control and experimental groups was determined using two-groups
two-tailed Student’s t test, with a level of statistical significance of P < 0.01.
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